-
2023-510227-30-00
Intestinal giardiasis
-
2024-510717-15-00
Acute myeloid leukemia
-
2024-513917-11-01
Adult patients with chronic lymphocytic leukemia/small
-
2024-513941-35-00
HIV Disease
-
2024-514360-70-00
Low-grade upper track urothelial carcinoma (LG-UTUC)
-
2024-516545-39-01
unresectable stage III – IV melanoma
-
2024-517040-65-02
Chronic kidney disease
-
2024-517130-17-00
FLT3-mutated Acute Myeloid Leukemia
-
2024-517396-20-00
Sarbecoviruses disease
-
2024-517639-35-00
Non-Hodgkin lymphomas (NHL)
-
2024-518293-13-01
Pulmonary embolism
-
2024-518644-21-01
Advanced KRAS- Mutant Solid Tumours
-
2024-519160-41-00
Hypertrophic scarring.
-
2024-519658-35-00
Primary localised prostate cancer
-
2024-519786-22-01
metastatic non-small cell lung cancer (NSCLC)
-
2024-520318-23-00
Patients with advanced soft-tissue sarcoma (leiomyosarc
-
2025-520482-52-03
Prostate cancer
-
2025-521163-12-01
Graves' Orbitopathy
-
2025-521551-23-01
prostate cancer
-
2025-521671-31-00
Relapsed/Refractory (R/R) and Minimal Residual Disease
-
2025-521902-17-00
Unresectable/metastatic Small cell Lung Cancer (SCLC)
-
2025-521989-95-00
Advanced/Metastatic Non-squamous Non-Small Cell Lung Ca
-
2025-522348-42-00
post-COVID syndrome (long COVID)
-
2025-522659-24-00
Ovarian carcinoma